A randomised controlled trial of 3 strategies for the treatment of ARV naive HIV infected patients with tuberculosis

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201105000291300

Enrollment

1125

Registered

2011-04-26

Start date

2011-05-02

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV/AIDS Tuberculosis

Interventions

Standard strategy

Early ARV

High dose Rifampicin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Main inclusion criteria: o Male or female aged 18 or over o ARV naïve patients HIV + with CD4 cells more than 50 o All types of TB disease with bacteriological confirmation o Written informed consent

Exclusion criteria

Exclusion criteria: Main exclusion criteria: o Pregnant women or lactating women or women who are unwilling to use contraception o HIV-2 infected patients

Design outcomes

Primary

Measure	Time frame
Mortality from all causes	—

Secondary

Measure	Time frame
Mortality from all causes ;Type, frequency and severity of Adverse Events (AEs) ;Percentage of TB relapse and TB recurrence ;Plasma concentrations of rifampicin, isoniazid, pyrazinamide and ethambutol	—

Countries

Benin, Guinea, Senegal

Contacts

Public ContactCorinne Merle

Department of Epidemiology and Infectious Diseases

corinne.merle@lshtm.ac.uk+44 2079 272826

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026